Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   September 2014
 
A LA UNE
10/10/2014 - Partnering Days and BlueSky Meeting : registration are open

Partnering Days 2014 will be held Friday, October 10th, 2014 at the Congress Center of the WTC Grenoble. Registration are open until October 3rd, 2014. This day is designed to allow exchanges between health actors in Rhône-Alpes and facilitate the emergence of new collaborations. This new edition should bring together the majority of health actors in Rhône-Alpes from industrial, SMEs, academia and hospital sectors. It will be organized around two key tools: thematic roundtables and BlueSky Meeting sessions of flash presentation of brainstorming project ideas and technology offers for SMEs.
Contact: Claudia Chagneau, R&D Project Manager - claudia.chagneau@lyonbiopole.com

Learn more


09/30/2014 - Three projects, accredited by Lyonbiopole, obtain public funding from the 18th Call for Projects of the FUI

After their accreditation by Lyonbiopole, worldwide competitiveness cluster, the new projects GLIOMTRACKER, PHOSA and SMARTBANDAGE have been selected by the FUI. Since 2005, Lyonbiopole has accredited 165 multi-partner R&D projects for a total R&D investment of € 733 million of which € 300 million have been obtained.
Contact: Claudia Chagneau, R&D Project Manager -claudia.chagneau@lyonbiopole.com 

Learn more


09/18/2014 - Accinov obtains the status of pharmaceutical facility

Lyonbiopole announces that the French Health authority (ANSM) delivered to Accinov, its Innovation Centre, the authorization to open a pharmaceutical site. This authorization will allow Accinov to support the companies hosted in the Centre for the production of biological drugs for clinical trials in particular with the pharmaceutical responsibility of Accinov.
Contact: Sylvain Peyrache, Accinov, Innovation manager - sylvain.peyrache@accinov.com

Learn more



ZOOM SUR
Genel

On July 3rd, 2014, the start-up project Genel, hosted at the Grenoble business incubator GRAIN was established successfully.The company was created by Gaëlle Saint- Auret, PhD in Cell Biology, Functional Genomics specialist and Celine Paillier, 18 years of management experience in the biotechnology industry. Both passionated by the Human Health Research, they decided during their meeting in 2013 to pool their expertise to provide researchers with innovative solutions.

 

Learn more



A LA UNE
3/11/2014 - Meet major health actors in Japan on the occasion of Bio Europe (Frankfurt)

Lyonbiopole and its bioXclusters European partners (Biocat, bioPmed and BioM) organize on November 3rd, 2014 (from 15:00 to 18:00), during BIO Europe (Frankfurt) a meeting between Japanese and European players of the Health sector. This session provides a unique opportunity for European companies and clusters participating to the BIO-Europe fair to get an overview of the strengths of the health sector in Japan and to forge links with the Association of bio-industries in Japan (JBA), gathering the four major national clusters and their companies.
Contact: Emilie Roméo, European Project manager - emilie.romeo@lyonbiopole.com

3-5/11/2014 - Enjoy a discount and participate to Bio Europe 2014


For the upcoming BIO Europe, which will take place in Frankfurt from November 3rd to 5th, 2014, Lyonbiopole, through its partnership with Ubifrance and EBD, makes you benefit from various discounts on access to the convention. Moreover, in the context of this event, the industry experts in our network are at your disposal to accompany you on your respective markets and optimize your chances of success. 
Contact: Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com

Learn more


11/12-15/2014 - MEDICA-COPAMED Exhibition

Lyonbiopole and I-Care Clusterin partnership with UbiFrance invite companies of the Rhône-Alpes region to participate to MEDICA COPAMED-2014 Exhibition wich will be held from  November 12th to 15th 2014 in Düsseldorf (Germany). Visit Europe's largest conference on MedicalesTechnologies & Medical Devices theme.
Contact: Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com

Learn more


11/28/2014 - 6th edition of the Lyonbiopole’s Private Inv€stment Day


For the 6th time, Lyonbiopole organizes the Private Inv€stment Day on Friday, November 28th 2013, from 8.00 am to 3.00 pm. This event, dedicated to SMEs and private investors aims to foster interactions between companies, new entrepreneurs and investors of every kind. This day will be organized around moments of networking (roundtables, testimony and breaks) and company and project presentations.
Contact: Kevin Romani, SMEs Developement Director  kevin.romani@lyonbiopole.com

Learn more



AGENDA
Partnering Days & BlueSky Meeting
October 10th 2014 - Grenoble, France
Bio-Europe 2014
From November 3rd to 5th, 2014 - Frankfurt, Germany
Medica Copamed
From November 12th to 15th 2014 - Dusseldorf, Germany
4th Munich Biomarker Conference
From November 25th to 26th, 2014 - Munich, Germany
Private Inv€stment Day
November 28th, 2014 - Lyon, France
Biovision 2015
From April 15th to 16th, 2015, Lyon - France
2015 BIO International  Convention
From June 15th to 16th, 2015, Philadephia - US
 
A LA UNE
09/2014 - Horizon 2020 Health – calls for projects open

Several calls for projects in the H2020 "Health, demographic change and well-being" challenge, are open. They are designed to support collaborative projects to improve the quality of life of European citizens and the economic viability of health systems. 2 types of calls are opened: "Calls H2020-PHC-2015 2-stages" (1st deadline = 10/14/2014) and "Calls H2020-PHC-2015 one-step" (deadline = 2/24/2015). Find all the details here. Project holders are funded at 100 % on most of the topics. Other calls are open under H2020 priority 2 "Industrial leadership", including FET calls (dedicated to disruptive innovation). More information here. Lyonbiopole supports you to build up European projects.
Contact: Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

09/2014 -  H2020 SME instrument


H2020 program includes the SME instrument. It aims to fill gaps in the high-risk funding of innovation and give a strong boost to reach innovation. It targets the highly innovative SMEs with a strong ambition to develop, grow and internationalize;  focusing on the delivery of new products, services or processes on the market. For SMEs in the health sector, the SME instrument is focused on the PHC-12 Clinical research for the validation of biomarkers and / or diagnostic medical devices line. The project can be presented by a single SME, and different phases depending on the maturity of the project.  Reminder of deadlines in 2014: Phase 1 project = 12/17/2014 / Phase 2 project = 09/10/2014 - 17/12/2014. Lyonbiopole supports you to build up European projects.
Contact: Emilie Romeo, European Project Manager - emilie.romeo@lyonbiopole.com

09/2014 – IMI call for projects open

The Innovative Medicines Initiative (IMI) launched its first call for projects under the IMI 2 on July 9th. The topics proposed in the first call are: - Translational Approaches to disease modifying therapy of type 1 diabetes mellitus - Discovery and validation of novel endpoints dry age-related macular degeneration and diabetic retinopathy. Deadline for submission: November 12th, 2014. Find all the details on the IMI website. IMI encourages the participation of SMEs, patient organizations, regulatory authorities, academic teams, industry, hospitals and other organizations. Lyonbiopole supports you to build up European projects
Contact: Emilie Roméo, European Project Manager- emilie.romeo@lyonbiopole.com

Learn more



A LA UNE
09/18/2014 - Welcomed Massachusetts Governor at Lyonbiopole

Lyonbiopole in partnership with ONLYLYON, welcomed September 18th of this year, Deval Patrick, Governor of Massachusetts come to Lyon with a delegation of the Massachusetts Life Science Center (MLSC) represented in particular by its President Susan Windham-Bannister. Key player of the Boston health ecosystem, the MLSC, is endowed with a budget of about one billion dollars over 10 years and has for mission to invest in innovation, research, development and marketing of products or health services.

09/09/2014 - Ten projects accredited by Lyonbiopole selected by the National Research Agency

After accreditation by Lyonbiopole, 10 collaborative projects were selected through 2014 calls for proposals of the National Research Agency. Since its creation in 2005, Lyonbiopole has accredited 93 NRA collaborative projects representing a total investment of € 160 million for which € 53 million of state aid were obtained (without 2014 NRA projects).
Contact: Claudia Chagneau, R&D Project Manager - claudia.chagneau@lyonbiopole.com

09/17/2014 - Lyonbiopole’s members meet with Merck Serono

Aiming to develop partnerships between big pharma and SME, Lyonbiopole organized on October 17th 2014, a partnering day with Merck Serono. This event took place at Merck Serono French Headquarter in presence of Pierre Henry Longeray the CEO of the company. The event was structured around a workshop gathering 10 SMB’s specialized on personalized medicine and offer of global healthcare for patient offer and a general conference on Merck Serono activity and partnering opportunities gathering 40 participants. The meeting ended with a networking lunch where participants had the opportunity to exchange with Merck Serono collaborators.    
Contact: Simon Gudin, SMBs’ Development Project Manager – simon.gudin@lyonbiopole.com

09/23/2014 - Transgene Appoints Eric Quéméneur, PhD as Executive Vice President

Transgene announced the appointment of Eric Quéméneur, PhD as Executive Vice President in charge of Research and Development. In this position, he will lead all of the Company’s research activities, from discovery through pre-clinica.

Learn more


09/23/2014 - CALIXAR and VirPath develop a new manufacturing process

CALIXAR, a start-up providing services focused on membrane proteins, and VirPath, an academic lab specialized in the study of influenza viruses, today announce a breakthrough in the manufacturing of high performance vaccines. Their current focus is on vaccines for influenza viruses.

Learn more


09/15/2014 -  Competence Biotech : proposal to share skills

Today Competence biotech is recruiting quality insurance staff for its members. 2 health R&D companies of the Lyon district and 2 of the Grenoble district will be sharing the time and skill of the recruited persons. This search in progress can be completed by the expectations of other companies having the same need. For more information contact Odile Pfennig via contact@competence-biotech.com  or by phone 06 44 87 44 27.

09/12/2014 - Ethera weclomes its new Chief Executive Officer

Since its creation in 2010, Ethera has become a key player in the field of indoor air quality. The company has developed innovative solutions for the diagnosis, monitoring and elimination of chemical pollution from the indoor air of public and private buildings.

Learn more


09/10/2014 - Alizé Pharma raises 5 million

Alizé Pharma SAS announces that it has closed a new financing round of EUR 5 million. The funds will be used to continue the clinical program for AZP-531, including the set-up and completion of two clinical trials: a Phase II trial in hyperphagia associated with Prader-Willi syndrome and a Phase Ib trial in type 2 diabetes.

Learn more


09/09/2014 - Poxel raises 10 M€ with new investors

Poxel SA announces that it has raised €10 million ($13.5 million) through a Series B extension with the Large Venture investment division of Bpifrance and a debt facility from Kreos Capital. The funds will be used to accelerate the development of the company’s lead program, Imeglimin, a novel anti-diabetic agent and to move forward a direct AMPK activator program which has proven benefits in controlling hyperglycemia and dyslipidemia and is now ready for phase 1 clinical trials.

Learn more


08/27/2014 - Innate Pharma gets the orphan drug status

Innate Pharma SA announced that the European Commission has granted orphan drug designation to IPH4102 for the treatment of cutaneous T-cell lymphoma (CTCL). CTCL is a group of rare cutaneous lymphomas of T lymphocytes with poor prognosis and few therapeutic options at advanced stages. IPH4102 is a first-in-class cytotoxic anti-IR3DL2
antibody, aiming at destroying CTCL cancer cells.

Learn more


08/25/2014 - Adocia starts a clinical trial of phase III in India

Adocia announced the initiation of a clinical Phase III study in India of BioChaperone® PDGF-BB, the Company’s innovative formulation of Platelet Derived Growth Factor (PDGF-BB) for the treatment of diabetic foot ulcers. This follows the approval given by the Drug Controller General of India (DCGI) on August 22nd, 2014. The folder for this clinical trial was filed in September 2012, but the processing of the application had been delayed by the internal reorganization of the Indian regulatory agency.

Learn more


08/06/2014 - Valneva announces a new agreement with GeoVax

European biotechnology company Valneva SE announced that it has signed a clinical development license agreement with the US firm GeoVax Labs, Inc. , to develop MVAbased vaccines in Valneva’s EB66® vaccine production cell line.

Learn more


28/07/2014 - Bioaster, gouvernance's evolutions

In last months, BIOASTER team has expanded considerably passing from fifty people to over eighty since last September. Bioaster governance is evolving.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |